These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38778019)

  • 1. Quantifying the economic value of earlier and enhanced management of anorexia nervosa for adults in England, Germany and Spain: improving the care pathway.
    McDaid D; Treasure J; Fernández-Aranda F; Herpertz-Dahlmann B; Quoidbach V; Dickson S; Gorwood P
    Eur Psychiatry; 2024 May; 67(1):e43. PubMed ID: 38778019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised controlled multicentre trial of treatments for adolescent anorexia nervosa including assessment of cost-effectiveness and patient acceptability - the TOuCAN trial.
    Gowers SG; Clark AF; Roberts C; Byford S; Barrett B; Griffiths A; Edwards V; Bryan C; Smethurst N; Rowlands L; Roots P
    Health Technol Assess; 2010 Mar; 14(15):1-98. PubMed ID: 20334748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population-based cost-offset analyses for disorder-specific treatment of anorexia nervosa and bulimia nervosa in Germany.
    Bode K; Götz von Olenhusen NM; Wunsch EM; Kliem S; Kröger C
    Int J Eat Disord; 2017 Mar; 50(3):239-249. PubMed ID: 28152200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of a randomised controlled trial for anorexia nervosa in adolescents.
    Byford S; Barrett B; Roberts C; Clark A; Edwards V; Smethurst N; Gowers SG
    Br J Psychiatry; 2007 Nov; 191():436-40. PubMed ID: 17978324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MOSAIC study - comparison of the Maudsley Model of Treatment for Adults with Anorexia Nervosa (MANTRA) with Specialist Supportive Clinical Management (SSCM) in outpatients with anorexia nervosa or eating disorder not otherwise specified, anorexia nervosa type: study protocol for a randomized controlled trial.
    Schmidt U; Renwick B; Lose A; Kenyon M; Dejong H; Broadbent H; Loomes R; Watson C; Ghelani S; Serpell L; Richards L; Johnson-Sabine E; Boughton N; Whitehead L; Beecham J; Treasure J; Landau S
    Trials; 2013 May; 14():160. PubMed ID: 23721562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of focal psychodynamic therapy and enhanced cognitive-behavioural therapy in out-patients with anorexia nervosa.
    Egger N; Wild B; Zipfel S; Junne F; Konnopka A; Schmidt U; de Zwaan M; Herpertz S; Zeeck A; Löwe B; von Wietersheim J; Tagay S; Burgmer M; Dinkel A; Herzog W; König HH
    Psychol Med; 2016 Dec; 46(16):3291-3301. PubMed ID: 27609525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of anorexia nervosa in QALYs.
    Pohjolainen V; Räsänen P; Roine RP; Sintonen H; Koponen S; Karlsson H
    Nord J Psychiatry; 2017 Jan; 71(1):67-71. PubMed ID: 27643401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
    Tunis SL; Willis WD; Foos V
    Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inpatient versus outpatient care, partial hospitalisation and waiting list for people with eating disorders.
    Hay PJ; Touyz S; Claudino AM; Lujic S; Smith CA; Madden S
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD010827. PubMed ID: 30663033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The modelled cost-effectiveness of cognitive dissonance for the prevention of anorexia nervosa and bulimia nervosa in adolescent girls in Australia.
    Le LK; Barendregt JJ; Hay P; Sawyer SM; Paxton SJ; Mihalopoulos C
    Int J Eat Disord; 2017 Jul; 50(7):834-841. PubMed ID: 28323355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The modeled cost-effectiveness of family-based and adolescent-focused treatment for anorexia nervosa.
    Le LK; Barendregt JJ; Hay P; Sawyer SM; Hughes EK; Mihalopoulos C
    Int J Eat Disord; 2017 Dec; 50(12):1356-1366. PubMed ID: 29044637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and cost-effectiveness of cognitive behavior therapy-enhanced compared with treatment-as-usual for anorexia nervosa in an inpatient and outpatient routine setting: a consecutive cohort study.
    van den Berg E; Schlochtermeier D; Koenders J; de Mooij L; de Jonge M; Goudriaan AE; Blankers M; Peen J; Dekker J
    J Eat Disord; 2022 Jan; 10(1):2. PubMed ID: 34991730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.
    Woods B; Schmitt L; Jankovic D; Kearns B; Scope A; Ren S; Srivastava T; Ku CC; Hamilton J; Rothery C; Bojke L; Sculpher M; Harnan S
    Health Technol Assess; 2024 Jun; 28(28):1-238. PubMed ID: 38938145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chair-based yoga programme for older adults with multimorbidity: RCT with embedded economic and process evaluations.
    Tew GA; Wiley L; Ward L; Hugill-Jones JG; Maturana CS; Fairhurst CM; Bell KJ; Bissell L; Booth A; Howsam J; Mount V; Rapley T; Ronaldson SJ; Rose F; Torgerson DJ; Yates D; Hewitt CE
    Health Technol Assess; 2024 Sep; 28(53):1-152. PubMed ID: 39259017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain.
    Simpson KN; Jones WJ; Rajagopalan R; Dietz B
    Clin Drug Investig; 2007; 27(12):807-17. PubMed ID: 18020538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and testing of a health economic Markov model for treatment of anorexia nervosa.
    Svendsen VG; Lokkerbol J; Danner UN; Jansingh A; Evers SM; Wijnen BF
    Expert Rev Pharmacoecon Outcomes Res; 2022 Dec; 22(8):1243-1251. PubMed ID: 36047856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of direct and indirect costs in anorexia nervosa.
    Stuhldreher N; Wild B; König HH; Konnopka A; Zipfel S; Herzog W
    Int J Eat Disord; 2015 Jan; 48(1):139-46. PubMed ID: 24634140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare use and costs of adults with anorexia nervosa and bulimia nervosa in Taiwan.
    Tseng MM; Tu CY; Chang YT
    Int J Eat Disord; 2021 Jan; 54(1):69-80. PubMed ID: 33210331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focal psychodynamic therapy, cognitive behaviour therapy, and optimised treatment as usual in female outpatients with anorexia nervosa (ANTOP study): 5-year follow-up of a randomised controlled trial in Germany.
    Herzog W; Wild B; Giel KE; Junne F; Friederich HC; Resmark G; Teufel M; Schellberg D; de Zwaan M; Dinkel A; Herpertz S; Burgmer M; Löwe B; Zeeck A; von Wietersheim J; Tagay S; Schade-Brittinger C; Schauenburg H; Schmidt U; Zipfel S
    Lancet Psychiatry; 2022 Apr; 9(4):280-290. PubMed ID: 35294860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study.
    Tanajewski L; Harris R; Harman DJ; Aithal GP; Card TR; Gkountouras G; Berdunov V; Guha IN; Elliott RA
    BMJ Open; 2017 Jul; 7(6):e015659. PubMed ID: 28679676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.